Abstract
Increased understanding of psoriasis has led to a shift in treatments from non-specific immunosuppressants to targeted biologics. Studies in psoriasis have demonstrated minimal risk and substantial benefit. As a result, dermatologists and patients are more frequently choosing biologics as first-line treatments for moderate-to-severe disease as our biologics options have recently increased.
.| Original language | English |
|---|---|
| Pages (from-to) | s113-s114 |
| Journal | Journal of Drugs in Dermatology |
| Volume | 16 |
| Issue number | 8 |
| State | Published - 1 Aug 2017 |